Showing results (31-40 of 61) with videos related to
Sort By:
Pageof 7
Bioorganic & Medicinal Chemistry Letters|February 7, 2012
The discovery of aminopyrazines as novel, potent Na(v)1.7 antagonists: hit-to-lead identification and SARHoward Bregman, Hanh Nho Nguyen, Elma Feric, et al.Journal of Medicinal Chemistry|June 23, 2026
Discovery of SMD-6346: A Potent, Selective, and Orally Active SMARCA2 Degrader for Targeting SMARCA4-Deficient Human CancersLingying Leng, Liyue Huang, Wenbin Tu, et al.ACS Medicinal Chemistry Letters|June 6, 2014
Structure-based design of 2-aminopyridine oxazolidinones as potent and selective tankyrase inhibitorsHongbing Huang, Angel Guzman-Perez, Lisa Acquaviva, et al.Angewandte Chemie (International Ed. in English)|December 29, 2017
Design of the First-in-Class, Highly Potent Irreversible Inhibitor Targeting the Menin-MLL Protein-Protein InteractionShilin Xu, Angelo Aguilar, Tianfeng Xu, et al.Journal of Neuroinflammation|January 31, 2025
Rescue of in vitro models of CSF1R-related adult-onset leukodystrophy by iluzanebart: mechanisms and therapeutic implications of TREM2 agonismKelley C Larson, Frederick W Gergits, Abigail J Renoux, et al.Journal of Medicinal Chemistry|January 2, 2025
Discovery of High-Affinity SMARCA2/4 Bromodomain Ligands and Development of Potent and Exceptionally Selective SMARCA2 PROTAC DegradersLingying Leng, Wenbin Tu, Lin Yang, et al.Plos One|September 18, 2015
Inhibition of Inactive States of Tetrodotoxin-Sensitive Sodium Channels Reduces Spontaneous Firing of C-Fiber Nociceptors and Produces Analgesia in Formalin and Complete Freund's Adjuvant Models of PainDavid J Matson, Darryl T Hamamoto, Howard Bregman, et al.Journal of Medicinal Chemistry|June 28, 2019
Structure-Based Discovery of M-89 as a Highly Potent Inhibitor of the Menin-Mixed Lineage Leukemia (Menin-MLL) Protein-Protein InteractionAngelo Aguilar, Ke Zheng, Tianfeng Xu, et al.Bioorganic & Medicinal Chemistry Letters|December 9, 2008
Discovery of alpha-amidosulfones as potent and selective agonists of CB2: synthesis, SAR, and pharmacokinetic propertiesIsaac E Marx, Erin F DiMauro, Alan Cheng, et al.Journal of Medicinal Chemistry|July 1, 2021
Discovery of M-1121 as an Orally Active Covalent Inhibitor of Menin-MLL Interaction Capable of Achieving Complete and Long-Lasting Tumor RegressionMeng Zhang, Angelo Aguilar, Shilin Xu, et al.Pageof 7